Status:
RECRUITING
Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis
Lead Sponsor:
Yale University
Collaborating Sponsors:
Lilly PharmaceuticalCompany
Conditions:
Idiopathic Subglottic Stenosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation th...
Detailed Description
The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation th...
Eligibility Criteria
Inclusion
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- diagnosis of idiopathic subglottic stenosis
Exclusion
- History of active or latent tuberculosis infection
- History of inflammatory bowel disease
- Pregnancy or lactation
- Known allergic reactions to study drug
- Disease involving the vocal cords
- Individuals who are taking drugs known to trigger angioedema, including use acquired angioedema from drugs such as ACE inhibitors (e.g. Lisinopril) and nonsteroidal anti-inflammatory drugs (NSAIDs) and individuals with a history of other forms of angioedema such as hereditary and Clesterase deficiency
Key Trial Info
Start Date :
February 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05309616
Start Date
February 20 2025
End Date
April 1 2026
Last Update
February 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale New Haven Hospital
New Haven, Connecticut, United States, 06520